Novo Nordisk ADR retraces gains as the US FDA claims its weight loss drug Wegovy's advertising is false or misleading.

Novo Nordisk ADR narrowed its gains to less than 4.4%, after rising as much as 7.2% earlier. The US Food and Drug Administration told Novo Nordisk that the weight loss drug Wegovy's TV ad is either false or misleading.